Paul
06-05-2003, 02:55 AM
Omnitarg (2C4) is a monoclonal antibody and the first in a new class of agents developed by Genentech known as HER dimerization inhibitors (HDIs). It was developed to bind to the HER-2 receptor and block the interaction between HER-2 and other HER family members (i.e. HER1/EGFR HER2 HER3 and HER4). Technically it is designed to target tumors that have normal " rather than ""overexpressed" " HER2 protein. It is relevant because it may one day represent the Herceptin equivalent"" treatment for patients who are not HER-2 positive or who are not ""strongly"" HER-2 positive.
Importantly" the positive study data relates not only to breast cancer but to other cancers as well (e.g. prostate lung ovarian colon pancreas and sarcoma).
Importantly" the positive study data relates not only to breast cancer but to other cancers as well (e.g. prostate lung ovarian colon pancreas and sarcoma).